Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of LIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and BIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) in Healthy Population Aged 18 and Above
NCT05599516 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of LIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and BIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) in Healthy Population Aged 18 and Above
- Lead sponsor
- National Vaccine and Serum Institute, China
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- November 4, 2022
- Completion date
- December 31, 2023
- Enrollment
- 16,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.